If the FDA approves lonvo-z, Intellia expects it will be able to launch the drug, its first commercial product, in the first ...

The firm, founded based on research from Zhejiang University, is partnering with Walvax for logistical support for the investigator-initiated trial.

The firm also expects topline data from a trial of its gene therapy for rare eye diseases caused by mutations in the BEST1 gene in September.

The firm attributed a drop in revenue to losing the non-ambulatory indication on the product's label but expects sales revenue to rebound in 2027.

For the three months ended June 30, the firm reported greater net loss and general and administrative expenses as it awaits an FDA decision on the RAS inhibitor daraxonrasib.

Overall, the firm's sales were up 10 percent and beat Wall Street expectations, but net income took a hit from recent ...

The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...

The Phase II trial is testing if neoadjuvant targeted therapies for HER2-positive and claudin 18.2-positive tumors can allow patients to preserve affected organs.

Universities and research organizations say the proposed rule would politicize the federal research grant process.

Pathos will be responsible for AZD4241's early clinical development using its AI platform to design clinical trials.

The clinical research company will help Medera with recruitment, data quality, and regulatory filings for cardiovascular disease and beyond.

RAG-1C is designed to deliver small activating RNA to reactivate the CDKN1A gene, increase p21 expression, and inhibit cellular proliferation in the eye.